Introduction {#ss1}
============

The prevalence of type 2 diabetes mellitus in Japan is increasing[^1--3^](#b1 b2 b3){ref-type="ref"}. Indeed, findings from a recent survey carried out by the Japanese Health Service Bureau suggested that approximately 8.9 million Japanese have glycosylated hemoglobin A1c (HbA~1c~) values ≥6.5% or are taking glucose‐lowering medication and are therefore highly likely to have diabetes[^4^](#b4){ref-type="ref"}. The same survey also suggested that approximately 21.1 million Japanese have HbA~1c~ values between 6.0% and 6.5%, and therefore may have diabetes[^4^](#b4){ref-type="ref"}. Unfortunately, currently available treatments for type 2 diabetes in Japan, including insulin, sulfonylurea (SU), biguanide (BG) and thiazolidinedione (TZD), do not always provide adequate glycemic control[^5--7^](#b5 b6 b7){ref-type="ref"}, and can have adverse side‐effects, such as hypoglycemia and weight gain[^8,9^](#b8 b9){ref-type="ref"}. Given the increasing prevalence of type 2 diabetes in Japan and the risks associated with current treatment, there is a need for new therapies that provide adequate glycemic control.

Exenatide is a glucagon‐like peptide‐1 receptor agonist that has been shown to improve glycemic control, decrease bodyweight and improve β‐cell function in patients with type 2 diabetes from Western countries[^10--15^](#b10 b11 b12 b13 b14 b15){ref-type="ref"}. Consequently, exenatide b.i.d. has been approved in the USA and Europe for use as adjunct therapy, with diet and exercise, for patients with type 2 diabetes who have not achieved adequate glycemic control with metformin (Met), SU or a combination of Met and SU. Exenatide has also been approved in the USA for use as monotherapy adjunct to diet and exercise, and as adjunct therapy with TZD or combined Met and TZD. We have recently reported the findings of the first phase III, double‐blind, randomized controlled trial of exenatide b.i.d. in Japan[^16^](#b16){ref-type="ref"}. After 24 weeks of adjunct treatment with exenatide, we found that participants with type 2 diabetes and suboptimal glycemic control had improved glycemic control and, at a 10‐μg b.i.d. dose, decreased bodyweight. Exenatide also had a favorable safety profile and was generally well tolerated. In October 2010, exenatide b.i.d. was approved in Japan as an adjunct therapy for patients with type 2 diabetes who had not achieved adequate glycemic control with SU, alone or in combination with BG or TZD.

The purpose of the present extension study was to determine the long‐term (52 weeks) safety and efficacy of adjunct exenatide treatment in Japanese patients with type 2 diabetes and suboptimal glycemic control.

Materials and Methods {#ss2}
=====================

Study Design {#ss3}
------------

The present study was a 28‐week, open‐label extension study carried out at 23 centers in Japan. Participants were enrolled immediately after completing a 24‐week, double‐blind, randomized controlled trial (ClinicalTrials.gov registration number NCT00577824)[^16^](#b16){ref-type="ref"}. In the 24‐week trial, a total of 181 participants were randomized (1:2:2) to receive placebo, exenatide 5 μg or exenatide 10 μg b.i.d. Participants in the placebo group were further randomized (before starting the 24‐week trial) to receive exenatide 5 μg or exenatide 10 μg during the extension study. Throughout the 52‐week study, participants were instructed to inject exenatide (Eli Lilly and Company, Indianapolis, IN, USA) or placebo 15 min before both the morning and evening meals; however, injections made between 0 and 60 min before meals were allowed.

The study was approved by the Institutional Review Board of each participating center and was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All study participants provided written informed consent.

Participants {#ss4}
------------

The main study inclusion criteria at the time of enrolment in the initial study[^16^](#b16){ref-type="ref"} were as follows: a diagnosis of type 2 diabetes mellitus according to the Japan Diabetes Society (JDS)[^17^](#b17){ref-type="ref"} and the World Health Organization[^18^](#b18){ref-type="ref"} definitions; currently on SU monotherapy, SU and BG combination therapy, or SU and TZD combination therapy without any change in dose within 90 days of enrolment; suboptimal glycemic control as defined by the JDS[^17^](#b17){ref-type="ref"} (i.e. HbA~1c~ value ≥ 7.4% and ≤10.4%); age between 20 and 75 years; and bodyweight ≥ 50 kg. Patients taking α‐glucosidase inhibitors or short‐acting insulin secretion inducers were eligible for inclusion, but stopped taking these drugs before beginning the study.

The main study exclusion criteria at the time of enrolment in the initial study[^16^](#b16){ref-type="ref"} were as follows: treatment with exogenous insulin or any drug affecting gastrointestinal motility within 90 days of enrolment; currently on triple therapy (i.e. SU, BG and TZD); any clinically significant gastrointestinal or hepatic disorder; suspected malignant tumor or a history of malignant tumor within 5 years of enrolment; serum creatinine ≥ 1.5 mg/dL in men or ≥1.4 mg/dL in women; systolic blood pressure (sitting) ≥ 160 mmHg or diastolic blood pressure (sitting) ≥ 100 mmHg; fasting plasma glucose ≥ 250 mg/dL or casual blood glucose ≥ 350 mg/dL or at least one episode of severe hypoglycemia within 90 days of enrolment; and women who were breastfeeding, pregnant, intending to become pregnant during the study, not practicing a reliable method of contraception within 90 days of enrolment or unable to practice a reliable method of contraception during the study.

Interventions {#ss5}
-------------

From week 24 to week 28 (i.e. the first 4 weeks of the extension study), all participants received exenatide 5 μg, b.i.d. Participants who received exenatide (5 μg or 10 μg) in the 24‐week trial received the same dose of exenatide from week 28 to week 52 (exenatide 5 μg and exenatide 10 μg groups, respectively). Participants who received placebo in the 24‐week trial received exenatide 5 μg (placebo/exenatide 5 μg group) or exenatide 10 μg (placebo/exenatide 10 μg group) from week 28 to week 52.

Baseline clinical characteristics of participants in the exenatide groups were determined at week 0 and included all participants who received at least one dose of exenatide in the 24‐week trial. Baseline clinical characteristics of participants in the placebo/exenatide groups were determined at week 24. Follow‐up assessments were made every 4 weeks.

Efficacy Outcomes {#ss6}
-----------------

The following efficacy outcomes were recorded: change from baseline in HbA~1c~ values; the proportion of participants who achieved an HbA~1c~ value \< 7.4% and \<6.9% at week 52; fasting plasma glucose concentrations; seven‐point, self‐monitored blood glucose concentrations (SMBG; measured before breakfast, before lunch, before dinner, 2 h after starting each meal and before bedtime); bodyweight; serum lipid concentrations (total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol and triglyceride); and glycemic control, as indicated by 1,5‐anhydroglucitol concentrations. Please note that all HbA~1c~ values in the present study are expressed as National Glycohemoglobin Standardization Program equivalent values (i.e. JDS HbA~1c~ value + 0.4%)[^17^](#b17){ref-type="ref"}. We used the JDS definition of good glycemic control (i.e. HbA~1c~ value \< 6.9%)[^17^](#b17){ref-type="ref"}.

All laboratory tests were carried out using standard methods at a central laboratory (Bio Medical Laboratories Inc., Tokyo, Japan).

Safety Outcomes {#ss7}
---------------

###  {#ss8}

**Treatment‐Emergent Adverse Events ** Treatment‐emergent adverse events (TEAE) were coded and summarized using the Medical Dictionary for Regulatory Activities (version 12.0) and were defined as events that occurred during the treatment period or worsened from baseline. Only common TEAE, defined as TEAE with an incidence \>10% in the exenatide 10 μg group during the 52‐week study, and serious adverse events (SAE) are described.

###  {#ss9}

**Hypoglycemia ** Hypoglycemia was defined as the presence of signs or symptoms of hypoglycemia, regardless of blood glucose concentration. Decreased blood glucose was defined as a blood glucose concentration \< 70 mg/mL in the absence of signs or symptoms of hypoglycemia.

###  {#ss10}

**Exenatide Antibody Status ** Participants were considered to have treatment‐emergent exenatide antibodies if antibodies were undetectable at baseline and detectable (a titer ≥ 25) at any subsequent visit. Participants were also considered to have treatment‐emergent exenatide antibodies if antibodies were detectable at baseline and the titer increased by three dilution factors at any subsequent visit. Exenatide antibody concentrations were measured by Millipore Corporation (St. Charles, MO, USA) using a solid‐phase enzyme‐linked immunosorbent assay[^10^](#b10){ref-type="ref"}.

Statistical Analysis {#ss11}
--------------------

Continuous variables are presented as mean ± standard deviation (SD). Categorical variables are presented as frequency and percentage.

Results {#ss12}
=======

Participant Disposition {#ss13}
-----------------------

Of the 152 participants who completed the 24‐week trial, 150 were enrolled in the 28‐week extension study, and 137 completed the extension study ([Figure 1](#f1){ref-type="fig"}). A total of 13 participants discontinued the extension study. The most common reason for discontinuation was adverse events (8/13 participants).

![ Participant flow diagram.](jdi-2-448-g1){#f1}

Baseline Clinical Characteristics {#ss14}
---------------------------------

Participants in the different groups had similar baseline clinical characteristics ([Table 1](#t1){ref-type="table-wrap"}). The proportions of participants taking different combinations of oral anti‐diabetic drugs were similar between the groups.

######  Baseline characteristics of Japanese participants with type 2 diabetes mellitus and suboptimal glycemic control

  Characteristic                               Placebo/exenatide 5 μg  (*n* = 17)\*   Placebo/exenatide 10 μg  (*n* = 16)\*   Exenatide 5 μg  (*n* = 72)†   Exenatide 10 μg  (*n* = 72)†
  -------------------------------------------- -------------------------------------- --------------------------------------- ----------------------------- ------------------------------
  Men, *n* (%)                                  12 (71)                                10 (63)                                 49 (68)                       49 (68)
  Age (years)                                  54 ± 12                                59 ± 11                                 59 ± 9                        59 ± 10
  Weight (kg)                                  67 ± 10‡                               72 ± 17‡                                67 ± 11                       69 ± 11
  BMI (kg/m^2^)                                24.6 ± 3.2‡                            26.4 ± 5.2‡                             25.0 ± 4.1                    25.8 ± 3.9
  Duration of type 2 diabetes (years)          11.7 ± 5.5                             12.7 ± 7.8                              12.2 ± 6.3                    11.6 ± 7.0
  HbA~1c~ (%)                                  8.6 ± 0.9‡                             8.1 ± 1.2‡                              8.7 ± 0.8                     8.6 ± 1.0
  Fasting plasma glucose (mg/dL)               161 ± 35‡                              147 ± 29‡                               164 ± 42                      164 ± 39
  Total cholesterol (mg/dL)                    195 ± 27‡                              192 ± 19‡                               204 ± 36                      202 ± 31
  HDL cholesterol (mg/dL)                      52 ± 10‡                               57 ± 13‡                                57 ± 15                       55 ± 11
  LDL cholesterol (mg/dL)                      120 ± 27‡                              115 ± 19‡                               124 ± 28                      125 ± 27
  Triglycerides (mg/dL)                        140 ± 73‡                              106 ± 49‡                               133 ± 95                      131 ± 70
  Oral anti‐diabetic agents§                                                                                                                                
   SU alone, *n* (%)                             1 (5.9)                                1 (6.3)                                 4 (5.6)                       8 (11.1)
   SU + α‐GI, *n* (%)                            1 (5.9)                                2 (12.5)                                1 (1.4)                       4 (5.6)
   SU + BG, *n* (%)                              7 (41.2)                               7 (43.8)                               33 (45.8)                     27 (37.5)
   SU + BG + α‐GI, *n* (%)                       4 (23.5)                               5 (31.3)                               22 (30.6)                     13 (18.1)
   SU + BG + meglitinide derivative, *n* (%)     0 (0.0)                                0 (0.0)                                 0 (0.0)                       1 (1.4)
   SU + TZD, *n* (%)                             3 (17.6)                               0 (0.0)                                 6 (8.3)                      12 (16.7)
   SU + TZD + α‐GI, *n* (%)                      1 (5.9)                                1 (6.3)                                 6 (8.3)                       7 (9.7)

Values are mean ± standard deviation, except where indicated.

\*Includes participants who were enrolled in the 28‐week extension study.

†Includes participants who were enrolled in the initial 24‐week trial and received at least one dose of exenatide.

‡These values were determined at the beginning of the 28‐week extension study.

§Taken at the time of providing informed consent.

α‐GI, α‐glucosidase inhibitors; BMI, body mass index; BG, biguanide; HbA~1c~, glycosylated hemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; SU, sulfonylurea; TZD, thiazolidinedione.

Efficacy Outcomes {#ss15}
-----------------

Exenatide treatment was associated with sustained decreases in HbA~1c~ values ([Figure 2a](#f2){ref-type="fig"}). In the exenatide 5 μg and exenatide 10 μg groups, the decreases in HbA~1c~ values that occurred during the first 24 weeks of treatment were generally maintained from week 24 to week 52. In the placebo/exenatide 5 μg and placebo/exenatide 10 μg groups, HbA~1c~ values were decreased from baseline (week 24) to week 52. Decreases from baseline in HbA~1c~ values were greater in the exenatide 10 μg and placebo/exenatide 10 μg groups than in the exenatide 5 μg and placebo/exenatide 5 μg groups.

![ Change from week 0 in (a) glycosylated hemoglobin A1c (HbA~1c~) values and (b) bodyweight after treatment with exenatide (5 or 10 μg) b.i.d. Participants in the placebo/exenatide groups received placebo for the first 24 weeks and exenatide for the following 28 weeks. Participants in the exenatide groups received exenatide for the entire 52 weeks. Values are means, with standard deviations shown as upward (placebo/exenatide 5 μg \[*n* = 16--18\] and exenatide 5 μg \[*n* = 60--72\] groups) or downward (placebo/exenatide 10 μg \[*n* = 11--17\] and exenatide 10 μg \[*n* = 48--72\] groups) error bars. Note: data were not available for all participants.](jdi-2-448-g2){#f2}

A greater proportion of participants in the exenatide 10 μg and placebo/exenatide 10 μg groups achieved HbA~1c~ target levels than participants in the exenatide 5 μg and placebo/exenatide 5 μg groups. Among participants who received exenatide for 52 weeks, 32 of 45 (71.1%) and 30 of 59 (50.8%) achieved an HbA~1c~ level of \<7.4% in the exenatide 10 μg and exenatide 5 μg groups, respectively. Similarly, 8 of 11 (72.7%) participants in the placebo/exenatide 10 μg group achieved an HbA~1c~ level of \<7.4% compared with 8 of 17 (47.1%) participants in the placebo/exenatide 5 μg group. Among participants who received exenatide for 52 weeks, 23 of 48 (47.9%) and 20 of 60 (33.3%) participants achieved an HbA~1c~ level of \<6.9% in the exenatide 10 μg and exenatide 5 μg groups, respectively. Similarly, 7 of 11 (63.6%) participants in the placebo/exenatide 10 μg group achieved an HbA~1c~ level of \<6.9% compared with 3 of 17 (17.6%) participants in the placebo/exenatide 5 μg group.

Fasting plasma glucose concentrations decreased from baseline in all groups after the start of exenatide treatment. The decrease in fasting plasma glucose concentration from baseline in participants in the exenatide 5 μg group and the exenatide 10 μg group after 24 weeks of treatment was maintained during the extension study. The mean (±SD) change from baseline in fasting plasma glucose concentration in the exenatide 5 μg group was −29.6 ± 37.1 mg/dL at week 24 and −16.4 ± 41.4 mg/dL at week 52. The mean (±SD) change from baseline in fasting plasma glucose concentration in the exenatide 10 μg group was −36.0 ± 36.3 mg/dL at week 24 and −29.8 ± 39.0 mg/dL at week 52. The mean (±SD) change from week 0 in fasting plasma glucose concentration in the placebo/exenatide 5 μg group was −8.2 ± 23.3 mg/dL at week 24 (baseline for this group) and −19.1 ± 36.9 mg/dL at week 52. The mean (±SD) change from week 0 in fasting plasma glucose concentration in the placebo/exenatide 10 μg group was −3.2 ± 27.1 mg/dL at week 24 (baseline for this group) and −31.6 ± 27.0 mg/dL at week 52.

Seven‐point, SMBG were decreased in all treatment groups at week 52 compared with baseline ([Figure 3](#f3){ref-type="fig"}). Decreases from baseline were most pronounced at the after breakfast and after dinner time‐points.

![ Changes in seven‐point, self‐monitored blood glucose concentrations after treatment with exenatide (5 or 10 μg) b.i.d. Plasma glucose concentrations were measured before breakfast, before lunch, before dinner, 2 h after starting each meal and before bedtime. Participants in the placebo/exenatide groups received placebo for the first 24 weeks and exenatide for the following 28 weeks. Participants in the exenatide groups received exenatide for the entire 52 weeks. Values are mean ± standard deviation (*n* = 16--18 in the placebo/exenatide 5 μg group; *n* = 11--17 in the placebo/exenatide 10 μg group; *n* = 59--72 in the exenatide 5 μg group; *n* = 46--72 in the exenatide 10 μg group). Note: data were not available for all participants.](jdi-2-448-g3){#f3}

Bodyweight decreased from baseline in the exenatide 10 μg group and in the placebo/exenatide 10 μg group, but did not change in either the exenatide 5 μg group or the placebo/exenatide 5 μg group ([Figure 2b](#f2){ref-type="fig"}). The bodyweight decrease from baseline in participants in the exenatide 10 μg group after 24 weeks of treatment was maintained during the extension study.

Plasma total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol and triglyceride concentrations were generally decreased from baseline or similar to baseline in the exenatide 5 μg and exenatide 10 μg groups at weeks 24 and 52, and in the placebo/exenatide 5 μg and placebo/exenatide 10 μg groups at week 52 (data not shown). Plasma concentrations of all lipids were within the normal range in all groups during the entire study.

Exenatide treatment was associated with sustained increases from baseline in 1,5‐anhydroglucitol concentrations. The mean (±SD) increases from baseline (week 0) in 1,5‐anhydroglucitol concentrations were 5.7 ± 4.4 μg/mL and 5.5 ± 4.4 μg/mL at week 24, and 3.3 ± 3.7 μg/mL and 4.5 ± 4.1 μg/mL at week 52 in the exenatide 5 μg group and the exenatide 10 μg group, respectively. The mean (±SD) increases from baseline (week 24) in 1,5‐anhydroglucitol concentrations were 2.7 ± 3.5 μg/mL and 6.7 ± 4.9 μg/mL at week 52 in the placebo/exenatide 5 μg group and the placebo/exenatide 10 μg group, respectively.

Safety Outcomes {#ss16}
---------------

The majority of common TEAE in the exenatide 5 μg and exenatide 10 μg groups occurred during the first 24 weeks, as shown by similar incidence rates between the first 24 weeks and the entire 52 weeks ([Table 2](#t2){ref-type="table-wrap"}). Mild hypoglycemia and nausea were the most common TEAE. With the exception of six episodes of moderate hypoglycemia in two patients in the exenatide 10 μg group, all episodes of hypoglycemia were mild in severity. In all groups, the incidences of hypoglycemia and nausea were highest within the first 4--8 weeks after starting exenatide treatment. Few participants who were randomized to receive exenatide for 52 weeks experienced hypoglycemia (5/144 participants) or nausea (1/144 participants) for the first time during the extension study. No TEAE specifically occurred during the extension study only (data not shown).

######  Common treatment‐emergent adverse events during the 24‐week, double‐blind study (24 weeks: placebo and exenatide groups), the extension study (28 weeks: placebo/exenatide groups only) and the entire study (52 weeks cumulative: exenatide groups only)

  Treatment‐emergent adverse event\*   24 Weeks   28 Weeks   24 Weeks    52 Weeks                            
  ------------------------------------ ---------- ---------- ----------- ----------- ----------- ----------- -----------
  Hypoglycemia, *n* (%)                8 (22.9)   5 (29.4)   12 (75.0)   37 (51.4)   42 (58.3)   40 (55.6)   44 (61.1)
  Nausea, *n* (%)                      3 (8.6)    6 (35.3)   8 (50.0)    18 (25.0)   26 (36.1)   18 (25.0)   27 (37.5)
  Blood glucose decreased, *n* (%)     4 (11.4)   4 (23.5)   4 (25.0)    10 (13.9)   18 (25.0)   14 (19.4)   24 (33.3)
  Nasopharyngitis, *n* (%)             8 (22.9)   4 (23.5)   3 (18.8)    8 (11.1)    9 (12.5)    24 (33.3)   22 (30.6)
  Vomiting, *n* (%)                    1 (2.9)    1 (5.9)    4 (25.0)     3 (4.2)    12 (16.7)    4 (5.6)    15 (20.8)
  Constipation, *n* (%)                1 (2.9)    1 (5.9)     1 (6.3)    10 (13.9)   11 (15.3)   12 (16.7)   13 (18.1)
  Abdominal discomfort, *n* (%)        1 (2.9)    1 (5.9)    2 (12.5)     7 (9.7)    9 (12.5)    10 (13.9)   12 (16.7)
  Decreased appetite, *n* (%)          1 (2.9)    0 (0)       1 (6.3)     7 (9.7)    9 (12.5)     7 (9.7)    9 (12.5)
  Anorexia, *n* (%)                    1 (2.9)    0 (0)      3 (18.0)     2 (2.8)    8 (11.1)     2 (2.8)    8 (11.1)

\*Treatment‐emergent adverse events with an incidence \>10% in the exenatide 10 μg group during the first 24 weeks are shown.

†These participants received placebo for the first 24 weeks and exenatide for the following 28 weeks.

For the entire 52 weeks, the incidence of TEAE considered by the investigators to be related to the study drug was 80.6% (58/72 participants) in the exenatide 5 μg group and 88.9% (64/72 participants) in the exenatide 10 μg group.

A total of eight participants experienced SAE during the extension study.

One participant in the placebo/exenatide 10 μg group and one participant in the exenatide 5 μg group experienced pancreatitis. Both participants discontinued the study and recovered uneventfully. Both participants had gallstones, a known cause of pancreatitis; however, the investigators could not rule out a relationship between exenatide treatment and pancreatitis.

One participant in the exenatide 5 μg group experienced pneumonia, which was considered to be unrelated to the study procedures. However, the investigators could not rule out a relationship between pneumonia and exenatide treatment.

Three participants experienced two different SAE, including cerebral infarction and hemiplegia (placebo/exenatide 5 μg group, *n* = 1), cerebral circulatory failure and calculus ureteric (exenatide 5 μg group, *n* = 1), and diabetic retinopathy and retinal vein occlusion (exenatide 10 μg group, *n* = 1). Other SAE during the extension study included brain stem infarction (exenatide 10 μg group, *n* = 1) and large intestine carcinoma (exenatide 10 μg group, *n* = 1). All of these SAE were considered by the study investigators to be unrelated to exenatide treatment and the study procedures.

There were no increases between week 24 and week 52 in the proportion of participants in the exenatide 5 μg and exenatide 10 μg groups who tested positive for the exenatide antibody. The proportion of participants who tested positive for the exenatide antibody at week 24 was 63.1% (41/65) and 60.4% (32/53) in the exenatide 5 μg and exenatide 10 μg groups, respectively. Corresponding proportions at week 52 were 63.3% (38/60) and 61.2% (30/49).

Exenatide antibody status did not appear to influence changes in HbA~1c~ values or the incidence of TEAE, including hypoglycemia and nausea (data not shown).

Discussion {#ss17}
==========

This is the first study to examine the long‐term (52 weeks) safety and efficacy of exenatide b.i.d. in Japanese participants with type 2 diabetes and suboptimal glycemic control. Importantly, we observed a very low incidence of common TEAE during the second 28 weeks of treatment. We also found that the efficacy of exenatide (as shown by improved glycemic control) previously observed after 24 weeks of treatment[^16^](#b16){ref-type="ref"} was maintained after 52 weeks of treatment. Our findings suggest that long‐term exenatide has a similar safety profile to that observed in previous studies and is efficacious for improving glycemic control in Japanese patients with suboptimally controlled type 2 diabetes.

We found that long‐term treatment with exenatide was associated with generally mild severity TEAE, a low incidence of TEAE in the extension study and a low proportion of participants who discontinued in the extension study because of TEAE. In keeping with the findings of previous studies of Caucasian participants with type 2 diabetes[^11--14,19,20^](#b11 b12 b13 b14 b19 b20){ref-type="ref"}, we found that hypoglycemia and nausea were the most common TEAE associated with exenatide treatment and that the severity of these TEAE was generally mild to moderate. Also consistent with previous findings was our finding that TEAE were generally more common during the earlier stages of treatment than during the later stages of treatment[^11--13,19^](#b11 b12 b13 b19){ref-type="ref"}. Further, more than 75% of participants who received exenatide completed the 52‐week study. Similar completion rates have been reported in long‐term studies of exenatide involving Caucasian participants with type 2 diabetes[^14,21,22^](#b14 b21 b22){ref-type="ref"}.

Two participants in the present study experienced pancreatitis during the treatment period. Although a relationship between exenatide treatment and pancreatitis could not be ruled out by the study investigators in either case, both participants had gallstones, a known cause of pancreatitis. Furthermore, type 2 diabetes is also a known risk factor for acute pancreatitis[^23--25^](#b23 b24 b25){ref-type="ref"}. Several recent studies found that exenatide treatment was not associated with an increased risk of pancreatitis compared with other anti‐diabetic treatments[^24,26,27^](#b24 b26 b27){ref-type="ref"}. Nevertheless, the prescribing information for exenatide acknowledges that postmarketing cases of acute pancreatitis have been reported[^28^](#b28){ref-type="ref"}.

We found that long‐term exenatide treatment was associated with sustained improvement in glycemic control, as shown by decreased HbA~1c~ values from baseline, an increased proportion of participants achieving target HbA~1c~ values, decreased fasting plasma glucose concentrations and SMBG, and increased 1,5‐anhydroglucitol concentrations. Other researchers have also consistently reported that long‐term (1--3 years) exenatide treatment was associated with sustained improvement in glycemic control in Caucasian participants with type 2 diabetes[^14,19--22^](#b14 b19 b20 b21 b22){ref-type="ref"}. The present findings suggest that exenatide treatment is effective for long‐term glycemic control in Japanese patients with type 2 diabetes.

Similar to previous long‐term studies of Caucasian patients with type 2 diabetes and suboptimal glycemic control[^14,19--22,29^](#b14 b19 b20 b21 b22 b29){ref-type="ref"}, we found that exenatide 10 μg treatment was associated with sustained weight loss in Japanese participants with type 2 diabetes and suboptimal glycemic control. Our finding that exenatide 10 μg was associated with sustained weight loss is important given that bodyweight is known to influence glycemic control[^30^](#b30){ref-type="ref"}. Also worth noting is our finding that participants receiving exenatide 10 μg lost weight despite continuing to take oral anti‐diabetics, which are known to cause weight gain[^8,9^](#b8 b9){ref-type="ref"}. Interestingly, we found that exenatide 5 μg treatment was not associated with weight loss. Variable effects of exenatide 5 μg on weight loss have been reported in previous, shorter duration studies involving Caucasian participants with type 2 diabetes[^11,13^](#b11 b13){ref-type="ref"}. These different findings may reflect differences in the mean baseline body mass index of the study participants. Indeed, DeFronzo *et al.*[^12^](#b12){ref-type="ref"} reported that only participants with an initial body mass index ≥ 30 kg/m^2^ had significant weight loss after 30 weeks of exenatide 5 μg treatment, whereas all participant groups in the present study had a mean baseline body mass index \< 30 kg/m^2^.

The strengths of the present study include the multicenter design, the duration of exenatide treatment, the assessment of multiple indicators of glycemic control and the high participant retention rate during the extension study. The present study, however, does have several limitations that must be acknowledged, including the absence of a group who received placebo for 52 weeks and the lack of control of participant dietary and exercise habits. We did, however, include a placebo group for the initial 24‐week trial in which pronounced differences were observed between the placebo and exenatide treatment groups[^16^](#b16){ref-type="ref"}. Although different dietary and exercise habits might have confounded our results, we have no reason to believe that these habits would have been markedly different between groups. Furthermore, dietary and exercise habits are rarely strictly controlled in 'real world' clinical settings; hence, our demonstration of efficacy and weight loss (in the exenatide 10 μg group) despite this lack of control is important. Finally, we acknowledge that monitoring beyond 52 weeks is necessary to evaluate the continued efficacy of exenatide in Japanese patients with type 2 diabetes.

In conclusion, our findings from this open‐label extension study show that long‐term (52 weeks) treatment with exenatide b.i.d. has a safety profile similar to that observed previously and is associated with sustained improvement in glycemic control in Japanese patients with type 2 diabetes. Taken together, our findings suggest that exenatide may be a viable treatment option for Japanese patients with type 2 diabetes and suboptimal glycemic control.
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